In patients treated with second- or newer-generation drug-eluting stents (DES) who require repeat revascularization, one-fifth of patients have chronic stent recoil, a new study shows.

New findings reveal that early administration of ezetimibe with statins following a myocardial infarction (MI) significantly reduces the risk of future cardiovascular events when compared with delayed use or statin monotherapy. 

A review highlights the ongoing challenge of conduction disturbances (CDs) following transcatheter aortic valve replacement (TAVR), revealing that the incidence remains “in the double-digit range,” with permanent pacemaker implantation (PPI) rates exceeding 10%. 

According to a sub-analysis of the PROSPECT II trial, patients with recent non-ST elevation myocardial infarction (NSTEMI) and high baseline levels of high-sensitivity C-reactive protein (hsCRP) are more likely to have pan-coronary atherosclerosis and focal high-risk plaques. 

Findings from a new study reveal a notable national decline in aspirin use for cardiovascular disease prevention between 2015 and 2023, particularly in response to updated medical guidelines and recent clinical trials reviewing its routine use.

A new case report demonstrates the rare instance of a type A aortic dissection spontaneously sealing after transcatheter heart valve deployment, allowing for successful conservative management in a high-risk patient.

New research shows machine learning is useful in enhancing risk stratification for patients with aortic regurgitation (AR), including the description of 4 distinct phenoclusters within this patient population. 

Patients who receive 4-factor prothrombin complex concentrate (PCC) for bleeding complications during cardiac surgery have superior hemostatic and safety outcomes compared with patients who receive frozen plasma, a new analysis shows. 

Compared to surgery, transcatheter aortic valve replacement (TAVR) achieves similar valve hemodynamic performance and durability in low-risk patients with severe aortic stenosis (AS), according to new 5-year echocardiographic data from the PARTNER 3 trial.